A new chimeric antigen receptor T cell (CAR-T) therapy has delivered promising results in treating patients with an aggressive blood cancer, in results from a clinical trial led by Dr Claire Roddie and Professor Martin Pule (UCL Cancer Institute).
Read: Manufacturing Chemist; More: UCL News
Close
